Extracellular free potassium during synchronous activity induced by 4-aminopyridine in the juvenile rat hippocampus.
Field potential recordings and measurements of the extracellular concentration of free K+ ([K+]o) were made in the stratum radiatum of the CA3 subfield of hippocampal slices that were obtained from 12- to 17-day-old rats. Spontaneous, synchronous field potentials were recorded in the presence of the convulsant drug 4-aminopyridine (4AP, 50 microM). They consisted of interictal- (duration = 0.2-1.2 s; rate of occurrence = 0.3-1.3 Hz) and ictal-like epileptiform discharges (8-40 s; 4-38.10(-3) Hz), as well as large amplitude, negative-going potentials that preceded the onset of the ictal-like event. Such a temporal correlation suggested that the negative-going potential might facilitate the onset of ictal-like activity. Interictal- and ictal-like discharges were abolished by the AMPA/kainate receptor antagonist 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX, 10 microM), while the negative-going potential was selectively blocked by bicuculline methiodide (BMI, 10 microM). Hence it was presumably due to the activation of GABAA receptors. [K+]o increased up to 12.5 mM (7.9 +/- 2.7 mM, mean +/- S.D.) from a resting value of 3.25 mM during the BMI-sensitive potentials (which also corresponded to the onset of ictal-like events), and after a decline to approximately 5 mM it remained elevated throughout the ictal event. Small, transient increases in [K+]o (up to 3.7 mM) could be seen during each interictal-like event. Following blockade of interictal- and ictal-like discharges by CNQX increases in [K+]o (up to 11 mM; 7.3 +/- 2.1; half-width = 7.2 +/- 2.3 s) still accompanied the BMI-sensitive negative-going potentials.(ABSTRACT TRUNCATED AT 250 WORDS)
Louvel
J
J
Montreal Neurological Institute, McGill University, Que., Canada.
Avoli
M
M
Kurcewicz
I
I
Pumain
R
R
D015761:4-Aminopyridine / Q000494:pharmacology*; D018750:6-Cyano-7-nitroquinoxaline-2,3-dione; D000818:Animals; D000831:Animals, Newborn; D004594:Electrophysiology; D005110:Extracellular Space / Q000378:metabolism*; D006624:Hippocampus / Q000187:drug effects / Q000378:metabolism* / Q000502:physiology*; D011188:Potassium / Q000378:metabolism*; D011810:Quinoxalines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors
D011810:Quinoxalines; D018750:6-Cyano-7-nitroquinoxaline-2,3-dione; D015761:4-Aminopyridine; D011188:Potassium